In biopharma and medtech, partnership and deal activity often signals where the industry believes value will be created tomorrow—but many teams track deals reactively, missing patterns and valuation benchmarks. Roots Analysis, an independent competitive intelligence firm, delivers Deal Tracking that systematically monitors, analyzes, and interprets partnership agreements across R&D, licensing, services, M&A, and joint ventures.

Its framework tracks R&D agreements (co-development, clinical trial alliances), licensing deals (in/out/cross-licensing, asset monetization), service agreements (manufacturing, CDMO, supply, commercialization), and M&A/joint ventures (acquisitions, equity investments, long-term collaborations). The suite includes real-time deal monitoring (monthly/quarterly dashboards), partnership trend analysis (5–10 years of evolving models and frequencies), company-specific deal profiles, and deal valuation benchmarking (upfronts, milestones, equity structures, valuation patterns).

Clients have used this third-party tracking to evaluate strategic ADC manufacturing moves and optimize capital allocation decisions. For BD, corporate development, and strategy teams, independent deal tracking turns scattered announcements into a forward-looking view of partnership patterns, whitespace opportunities, and priority response areas.

See how Roots Analysis structures deal monitoring and valuation benchmarking to inform smarter BD and capital strategy: https://www.rootsanalysis.com/competitive-intelligence/deal-tracking/